Empagliflozin Induces Vascular Relaxation in Rat Coronary Artery Due to Activation of BK Channels
(Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - January 19, 2024 Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity Source Type: research
GSE249412 Single nucleus RNA-seq comparison of TYA018 HDAC6 inhibition and Empagliflozin SGLT2 inhibition to treat heart failure with preserved ejection fraction
Contributors : Sara Ranjbarvaziri ; Aliya Zeng ; Iris Wu ; Amara Greer-Short ; Farshidfar Farshad ; Ana Budan ; Emma Xu ; Reva Shenwai ; Matthew Kozubov ; Cindy Li ; Melissa Van Pell ; Francis Grafton ; Charles Mackay ; Xiaomei Song ; James Priest ; Gretchen Argast ; Mohammad A Mandegar ; Timothy Hoey ; Jin YangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHeart failure with preserved ejection fraction (HFpEF) is a prevalent health condition associated with high morbidity and mortality, but currently, there are few effective therapies. Our previous research showed ...
Source: GEO: Gene Expression Omnibus - January 18, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Author Correction: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction
Experimental & Molecular Medicine, Published online: 15 January 2024; doi:10.1038/s12276-023-01154-2Author Correction: Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction (Source: Experimental and Molecular Medicine)
Source: Experimental and Molecular Medicine - January 15, 2024 Category: Molecular Biology Authors: Inho Kim Hyun-Jai Cho Soo Lim Seung Hyeok Seok Hae-Young Lee Source Type: research
A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)
ConclusionOur results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes.Trial RegistrationjRCTs2051190029 and NCT04018365. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 13, 2024 Category: Endocrinology Source Type: research
Identification of risk factors associated with acute kidney injury in patients taking sodium ‐glucose cotransporter‐2 inhibitors
ConclusionsThe transient eGFR decline with SGLT2 inhibitor initiation should be expected and is generally not an indication to discontinue therapy. Future initiatives should be directed at increasing knowledge of monitoring recommendations for these agents. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 12, 2024 Category: Drugs & Pharmacology Authors: Christie Schumacher,
Amanda Chorpash,
Charlotte Bolch,
Kellye Eagan,
Sara Nimer,
Elizabeth Van Dril Tags: RESEARCH ARTICLE Source Type: research
Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea
CONCLUSION: There is a large discrepancy in real-world eligibility for empagliflozin between FDA & EMA labels and clinical trial criteria. Empagliflozin is cost-effective in HF patients regardless of ejection fraction in South Korea health care setting. The efficacy and safety of empagliflozin in real-world HF patients should be further investigated for a broader range of clinical applications.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01389843.PMID:38193327 | DOI:10.3346/jkms.2024.39.e8 (Source: J Korean Med Sci)
Source: J Korean Med Sci - January 9, 2024 Category: General Medicine Authors: Eui-Soon Kim Sun-Kyeong Park Jong-Chan Youn Hye Sun Lee Hae-Young Lee Hyun-Jai Cho Jin-Oh Choi Eun-Seok Jeon Sang Eun Lee Min-Seok Kim Jae-Joong Kim Kyung-Kuk Hwang Myeong-Chan Cho Shung Chull Chae Seok-Min Kang Jin Joo Park Dong-Ju Choi Byung-Su Yoo Jae Source Type: research
Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea
CONCLUSION: There is a large discrepancy in real-world eligibility for empagliflozin between FDA & EMA labels and clinical trial criteria. Empagliflozin is cost-effective in HF patients regardless of ejection fraction in South Korea health care setting. The efficacy and safety of empagliflozin in real-world HF patients should be further investigated for a broader range of clinical applications.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01389843.PMID:38193327 | DOI:10.3346/jkms.2024.39.e8 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - January 9, 2024 Category: Biomedical Science Authors: Eui-Soon Kim Sun-Kyeong Park Jong-Chan Youn Hye Sun Lee Hae-Young Lee Hyun-Jai Cho Jin-Oh Choi Eun-Seok Jeon Sang Eun Lee Min-Seok Kim Jae-Joong Kim Kyung-Kuk Hwang Myeong-Chan Cho Shung Chull Chae Seok-Min Kang Jin Joo Park Dong-Ju Choi Byung-Su Yoo Jae Source Type: research
The Effect of Sodium –Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled Trials
ConclusionOur findings suggest that adjunctive therapy with SGLT inhibitors results in a significant reduction in albuminuria, while their use is associated with a neutral effect on creatinine clearance, as a measure of renal function. Future renal outcome trials are needed to assess SGLT inhibitors ’ role in the pharmacological armamentarium against diabetic nephropathy in T1D. (Source: Diabetes Therapy)
Source: Diabetes Therapy - January 5, 2024 Category: Endocrinology Source Type: research
Rates of diabetic ketoacidosis with empagliflozin use during hospitalization for acute heart failure
AbstractThere is concern that sodium-glucose cotransporter-2 inhibitors during hospitalization for acute heart failure (aHF) may precipitate diabetic ketoacidosis (DKA). A retrospective study of all hospitalization encounters for aHF defined by a primary HF International Classification of Diseases (ICD)-10 code in 15 Kaiser Permanente Southern California medical cente rs hospitalized between January 1, 2021 and August 31, 2023 was performed to describe rates of DKA with empagliflozin use. DKA was defined by the presence of either a DKA ICD-10 code or ketoacidosis lab criteria (bicarbonate<18 mmol/L and urine ketone...
Source: Journal of Hospital Medicine - January 3, 2024 Category: Hospital Management Authors: Cheng ‐Wei Huang,
Janet S. Lee,
Ming‐Sum Lee Tags: BRIEF REPORT Source Type: research
Empagliflozin Improves Vascular Insulin Sensitivity and Muscle Perfusion in Persons with Type 2 Diabetes
Am J Physiol Endocrinol Metab. 2024 Jan 3. doi: 10.1152/ajpendo.00267.2023. Online ahead of print.ABSTRACTSodium glucose cotransporter 2 inhibitors (SGLT2is) improved MACE, heart failure and renal outcomes in large trials; however, a thorough understanding of the vascular physiologic changes contributing to these responses is lacking. We hypothesized that SGLT2i therapy would diminish vascular insulin resistance and improve hemodynamic function, which could improve clinical outcomes. To test this, we treated 11 persons with type 2 diabetes for 12 weeks with empagliflozin 10 mg/d and measured vascular stiffness, endothelial...
Source: American Journal of Physiology. Endocrinology and Metabolism - January 3, 2024 Category: Physiology Authors: Linda A Jahn Lee M Hartline William B Horton Kevin W Aylor Thi Nguyen Zhenqi Liu Eugene J Barrett Source Type: research
Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation
Acta Pharmacol Sin. 2024 Jan 3. doi: 10.1038/s41401-023-01217-0. Online ahead of print.ABSTRACTType 2 diabetes mellitus (T2DM) patients exhibit greater susceptibility to vascular calcification (VC), which has a higher risk of death and disability. However, there is no specific drug for VC therapy. NLRP3 inflammasome activation as a hallmark event of medial calcification leads to arterial stiffness, causing vasoconstrictive dysfunction in T2DM. Empagliflozin (EMPA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i), restrains hyperglycemia with definite cardiovascular benefits. Given the anti-inflammatory activity of EMP...
Source: Acta Pharmacologica Sinica - January 3, 2024 Category: Drugs & Pharmacology Authors: Xiao-Xue Li Zheng-Dong Chen Xue-Jiao Sun Yi-Qing Yang Hong Jin Nai-Feng Liu Source Type: research
Empagliflozin Improves Vascular Insulin Sensitivity and Muscle Perfusion in Persons with Type 2 Diabetes
Am J Physiol Endocrinol Metab. 2024 Jan 3. doi: 10.1152/ajpendo.00267.2023. Online ahead of print.ABSTRACTSodium glucose cotransporter 2 inhibitors (SGLT2is) improved MACE, heart failure and renal outcomes in large trials; however, a thorough understanding of the vascular physiologic changes contributing to these responses is lacking. We hypothesized that SGLT2i therapy would diminish vascular insulin resistance and improve hemodynamic function, which could improve clinical outcomes. To test this, we treated 11 persons with type 2 diabetes for 12 weeks with empagliflozin 10 mg/d and measured vascular stiffness, endothelial...
Source: Am J Physiol Endocri... - January 3, 2024 Category: Endocrinology Authors: Linda A Jahn Lee M Hartline William B Horton Kevin W Aylor Thi Nguyen Zhenqi Liu Eugene J Barrett Source Type: research
Empagliflozin Improves Vascular Insulin Sensitivity and Muscle Perfusion in Persons with Type 2 Diabetes
Am J Physiol Endocrinol Metab. 2024 Jan 3. doi: 10.1152/ajpendo.00267.2023. Online ahead of print.ABSTRACTSodium glucose cotransporter 2 inhibitors (SGLT2is) improved MACE, heart failure and renal outcomes in large trials; however, a thorough understanding of the vascular physiologic changes contributing to these responses is lacking. We hypothesized that SGLT2i therapy would diminish vascular insulin resistance and improve hemodynamic function, which could improve clinical outcomes. To test this, we treated 11 persons with type 2 diabetes for 12 weeks with empagliflozin 10 mg/d and measured vascular stiffness, endothelial...
Source: American Journal of Physiology. Endocrinology and Metabolism - January 3, 2024 Category: Physiology Authors: Linda A Jahn Lee M Hartline William B Horton Kevin W Aylor Thi Nguyen Zhenqi Liu Eugene J Barrett Source Type: research
